chr16-1229245-A-G

Variant summary

Our verdict is Likely benign. The variant received -1 ACMG points: 0P and 1B. BP4

The NM_024164.6(TPSB2):​c.445T>C​(p.Phe149Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: 𝑓 0.0 ( 0 hom., cov: 1)
Exomes 𝑓: 0.0 ( 0 hom. )
Failed GnomAD Quality Control

Consequence

TPSB2
NM_024164.6 missense

Scores

6
7

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: 1.75

Publications

0 publications found
Variant links:
Genes affected
TPSB2 (HGNC:14120): (tryptase beta 2) Tryptases comprise a family of trypsin-like serine proteases, the peptidase family S1. Tryptases are enzymatically active only as heparin-stabilized tetramers, and they are resistant to all known endogenous proteinase inhibitors. Several tryptase genes are clustered on chromosome 16p13.3. These genes are characterized by several distinct features. They have a highly conserved 3' UTR and contain tandem repeat sequences at the 5' flank and 3' UTR which are thought to play a role in regulation of the mRNA stability. These genes have an intron immediately upstream of the initiator Met codon, which separates the site of transcription initiation from protein coding sequence. This feature is characteristic of tryptases but is unusual in other genes. The alleles of this gene exhibit an unusual amount of sequence variation, such that the alleles were once thought to represent two separate genes, beta II and beta III. Beta tryptases appear to be the main isoenzymes expressed in mast cells, whereas in basophils, alpha-tryptases predominate. Tryptases have been implicated as mediators in the pathogenesis of asthma and other allergic and inflammatory disorders. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -1 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.40875176).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
TPSB2NM_024164.6 linkc.445T>C p.Phe149Leu missense_variant Exon 4 of 6 ENST00000606293.5 NP_077078.5 P20231A0A140VJT7

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
TPSB2ENST00000606293.5 linkc.445T>C p.Phe149Leu missense_variant Exon 4 of 6 1 NM_024164.6 ENSP00000482743.1 P20231

Frequencies

GnomAD3 genomes
AF:
0.00
AC:
0
AN:
5884
Hom.:
0
Cov.:
1
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.00
AC:
0
AN:
58876
AF XY:
0.00
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
Data not reliable, filtered out with message: AC0;AS_VQSR
AF:
0.00
AC:
0
AN:
383114
Hom.:
0
Cov.:
4
AF XY:
0.00
AC XY:
0
AN XY:
200886
African (AFR)
AF:
0.00
AC:
0
AN:
9954
American (AMR)
AF:
0.00
AC:
0
AN:
15756
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
11502
East Asian (EAS)
AF:
0.00
AC:
0
AN:
16600
South Asian (SAS)
AF:
0.00
AC:
0
AN:
40798
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
22550
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
1650
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
242614
Other (OTH)
AF:
0.00
AC:
0
AN:
21690
GnomAD4 genome
Data not reliable, filtered out with message: AC0;AS_VQSR
AF:
0.00
AC:
0
AN:
5884
Hom.:
0
Cov.:
1
AF XY:
0.00
AC XY:
0
AN XY:
2366
African (AFR)
AF:
0.00
AC:
0
AN:
402
American (AMR)
AF:
0.00
AC:
0
AN:
674
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
152
East Asian (EAS)
AF:
0.00
AC:
0
AN:
10
South Asian (SAS)
AF:
0.00
AC:
0
AN:
166
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
298
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
36
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
4006
Other (OTH)
AF:
0.00
AC:
0
AN:
96

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

not specified Uncertain:1
Jan 21, 2025
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.445T>C (p.F149L) alteration is located in exon 4 (coding exon 3) of the TPSB2 gene. This alteration results from a T to C substitution at nucleotide position 445, causing the phenylalanine (F) at amino acid position 149 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Uncertain
0.11
D
BayesDel_noAF
Uncertain
-0.080
CADD
Benign
17
DANN
Uncertain
0.98
Eigen
Benign
-0.29
Eigen_PC
Benign
-0.52
FATHMM_MKL
Benign
0.040
N
LIST_S2
Benign
0.65
T;T
M_CAP
Uncertain
0.25
D
MetaRNN
Benign
0.41
T;T
MetaSVM
Uncertain
-0.14
T
PhyloP100
1.7
PrimateAI
Uncertain
0.68
T
Sift4G
Benign
0.76
T;T
Vest4
0.42
MutPred
0.58
Gain of glycosylation at P150 (P = 0.076);.;
MVP
0.25
ClinPred
0.97
D
GERP RS
1.2
gMVP
0.36

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.050
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1309952439; hg19: chr16-1279246; API